Add time:08/12/2019         Source:sciencedirect.com

We have earlier postulated that the presence of a pyridazone ring fused with an anthracenedione moiety resulted in the analog’s ability to overcome multidrug resistance of tumor cells [J. Med. Chem. 1999, 42, 3494]. High cytotoxic activity of obtained anthrapyridazones [Bioorg. Med. Chem. 2003, 11, 561] toward the resistant cell lines, prompted us to synthesize the similarly modified acridine compounds. A series of pyridazinoacridin-3-one derivatives (2b–h) were prepared from the reaction of 9-oxo-9,10-dihydroacridine-1-carboxylate with POCl3, followed by addition of the appropriate (alkylamino)alkylhydrazines. In vitro cytotoxic activity toward sensitive and resistant leukemia cell lines: L1210, K562, K562/DX, HL-60, HL-60/VINC, and HL-60/DX, with various type of multidrug resistance (MDR and MRP) was determined. The compounds studied exhibited in comparison to the reference cytostatics (DX, MIT) desirable very low resistance indexes (RI). Variations have been observed depending upon the substituent and the type of drug exporting pump. The cytotoxic activities of examined compounds, as well as of model anthrapyridazone derivative PDZ, were lower than those of reference drugs (DX, MIT) due to their diminished affinity to DNA.

We also recommend Trading Suppliers and Manufacturers of 4-Acridinecarboxylic acid, 9-((3-(dimethylamino)propyl)amino)-1-nitro- , methyl ester (cas 116374-64-2). Pls Click Website Link as below: cas 116374-64-2 suppliers